Hepatocellular Carcinoma Surveillance In High‐Risk Patients With Cirrhosis:Contrast‐enhanced Ultrasound May Be A Choice

We read with interest the study by Kim HL et al.[1], who compare the cost-effectiveness of semiannual surveillance using magnetic resonance imaging (MRI) vs. ultrasonography (US) in patients with compensated cirrhosis. The results showed that semiannual surveillance using liver-specific contrast-enhanced MRI may be more cost-effective than US in patients with virus-associated compensated cirrhosis at sufficiently high hepatocellular carcinoma (HCC) risk despite the higher test cost of MRI. We completely agree with these valuable and interesting findings. After reading the article carefully, some issues may need to be discussed. This article is protected by copyright. All rights reserved.